AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals reported Q2 2022 net revenues of $0.6 million, marking a 133% increase year-over-year in commercial sales for DSUVIA. The company anticipates achieving $9 million in annual savings from a realigned cost structure initiated in June 2022, alongside an $84.1 million gain from extinguishing debt. AcelRx is on track for an EU launch of DZUVEO and pursuing Emergency Use Authorization for Niyad™ in 2023. The cash balance was $27.9 million as of June 30, 2022, and the company continues to reduce headcount to manage expenses.
- 133% increase in DSUVIA commercial sales compared to Q2 2021
- $9 million annual savings from cost structure realignment
- $84.1 million gain from extinguishment of debt
- On track for EU launch of DZUVEO in Q3
- Planning for Emergency Use Authorization for Niyad™ in 2023
- Net loss of $9.9 million in Q2 2021 compared to a net income of $70.7 million in Q2 2022 due to one-time gains
Advanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023
Projected annual savings of
Webcast and Conference Call to be held today at 4:30 p.m. EDT
HAYWARD, Calif., Aug. 11, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2022 financial results.
"Our commercial emphasis on procedural suites has resulted in a successful quarter of growth for DSUVIA, while also reducing our costs, allowing us to focus on our robust pipeline," stated Vince Angotti, Chief Executive Officer of AcelRx. "DSUVIA continues to demonstrate solid sales growth in the procedural suite setting, with adoption beginning across national accounts. Our European partner, Aguettant, also is gearing up for the launch of DZUVEO. This said, we remain mindful of our operating costs and plan to continue reducing our cash burn. Importantly, we remain in discussions with potential partners with the commercial resources to amplify the expected growth for DSUVIA."
Mr. Angotti continued, "We're focused on a potential Emergency Use Authorization for our lead nafamostat candidate, Niyad™, in 2023 as we are making solid progress across the supply chain. Additionally, our pre-filled syringes remain on track for NDA submissions this year. We believe each of these product candidates will provide multiple value-creating catalysts in the near-term."
• | In August, AcelRx announced: | |
° | An abstract, entitled, "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" was accepted for podium presentation at Plastic Surgery The Meeting 2022, October 27-30 in Boston, MA. | |
°
| An abstract, entitled, "The Impact of Sublingual Sufentanil on Postoperative Pain Control in Patients Undergoing Spine Surgery" (abstract # A4262) was accepted for e-Abstract presentation at the ANESTHESIOLOGY® 2022 annual meeting, being held October 21-25 in New Orleans, LA. | |
• | In June 2022, AcelRx realigned its cost structure to reduce headcount by approximately | |
• | In May 2022, AcelRx announced: | |
° | The publication of clinical data from an investigator-initiated trial in patients undergoing lengthy plastic surgery procedures performed under general anesthesia, where use of a single sufentanil sublingual tablet 30 mcg (SST; DSUVIA®) in conjunction with intravenous (IV) opioids was able to dramatically reduce postoperative opioid requirements compared to an equivalent dose of opioids administered only via the IV route. | |
° | The U.S. Food and Drug Administration (FDA) revised the DSUVIA Risk Evaluation and Mitigation Strategies (REMS) program to eliminate the 6-month healthcare setting audit requirement and reduce annual healthcare setting audits to a total of up to 400 sites that have received a shipment of DSUVIA in the past 6 months. | |
• | In May 2022, a key opinion leader webinar highlighting the market for and benefits of Niyad and LTX-608 with two internationally renowned acute kidney injury experts, Stuart Goldstein, MD, from Cincinnati Children's Hospital, and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. To listen to a replay of the event, click here or visit the Investors/News & Events section of the company website. | |
• | Advanced progress on Niyad supply chain with contract manufacturing agreements in place with a focus on obtaining an Emergency Use Authorization next year. | |
• | As of July 31, 2022, AcelRx has achieved 983 DSUVIA formulary approvals. | |
• | The cash, cash equivalents and short-term investments balance was |
• | Second quarter 2022 net revenues were |
• | Combined R&D and SG&A expenses for the second quarter of 2022 totaled |
• | In the quarter ended June 30, 2022, the company entered into a Termination Agreement with SWK Funding, LLC to terminate the royalty monetization related to Zalviso in Europe which resulted in an |
Net income for the second quarter of 2021 was
As previously announced, AcelRx will host a live conference call and webcast Thursday, August 11th at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Time) to discuss these financial results and provide other corporate updates.
Investors who wish to participate in the conference call may do so by dialing 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 for international callers. The conference ID is 10168540. The webcast will be accessible by visiting the Investors page of AcelRx's website at www.acelrx.com and clicking on the webcast link. The webcast will be accompanied by a slide presentation. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of AcelRx's website at www.acelrx.com.
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals. Sufentanil is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile, when delivered sublingually, avoids the high peak plasma levels and short duration of action observed with IV administration. DZUVEO has been approved by the European Medicines Agency and AcelRx's European commercialization partner, Aguettant, will market the drug in Europe.
This release is intended for investors only. For more information, including important safety information and black box warning for DSUVIA, please visit www.DSUVIA.com.
Nafamostat is a broad spectrum, synthetic serine protease inhibitor with anticoagulant, anti-inflamatory and potential anti-viral activities. Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. LTX-608 is a proprietary nafamostat formulation for direct IV infusion that will be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC) and acute pancreatitis.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and several product candidates. The product candidates include: Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S. being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings; two pre-filled, ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant; Niyad™, a regional anticoagulant for the extracorporeal circuit; and LTX-608, for the potential treatment of COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome and acute pancreatitis. DZUVEO is an approved product in Europe.
This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.
This press release contains forward-looking statements, including, but not limited to, statements related to maintaining commercial sales performance of DSUVIA, our plans to focus DSUVIA commercialization efforts on select markets and certain potential national accounts, DSUVIA partnering discussions with potential commercial entities, the potential European launch of DZUVEO by Aguettant, our plans to pursue a potential Emergency Use Authorization for Niyad and establish a supply chain to support such efforts, our plans to reduce cash burn and potentially reduce operating costs, our plans to potentially file NDAs for our developmental pre-filled syringe products and the timing of such filings, expected effect and scope of cost savings arising from our restructuring efforts, and potential near-term value-creating catalysts arising under our development pipeline. These and any other forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "believe," "expect," "expected," "anticipate," "may," "potential," "will," "should," "seek," "approximately," "intends," "plans," "estimates," "benefits," or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements, which are predictions, projections and other statements about future events that are based on current expectations and assumptions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied by such statements, including: (i) the risk that the restructuring of the Company could adversely affect our ability to successfully market DSUVIA in existing and in new and untested markets; (ii) risks relating to our ability to obtain regulatory approvals for the pre-filled syringe product candidates in-licensed from Aguettant; (iii) risks relating to our ability to successfully commercialize the pre-filled syringe product candidates in-licensed from Aguettant should we obtain such regulatory approvals; (iv) risks relating to our ability to obtain regulatory approvals for the nafamostat product candidates acquired from Lowell; (v) risks relating to our ability to obtain an Emergency Use Authorization for Niyad; (vi) risks relating to our ability to successfully commercialize the nafamostat product candidates acquired from Lowell should we obtain regulatory approvals and/or authorizations; (vii) risks relating to AcelRx's product development activities diverting AcelRx management's attention from ongoing commercial business operations; (viii) risks related to the ability of AcelRx to implement its development plans, forecasts and other business expectations; and (ix) risks related to unexpected variations in market growth and demand for AcelRx's commercial and developmental products and technologies. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, those described under the caption "Risk Factors" and elsewhere in AcelRx's annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the Securities and Exchange Commission (SEC) and any subsequent public filings. You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. To the degree financial information is included in this press release, it is in summary form only and must be considered in the context of the full details provided in AcelRx's most recent annual, quarterly or current report as filed or furnished with the SEC. AcelRx's SEC reports are available at www.acelrx.com under the "Investors" tab. Except to the extent required by law, AcelRx undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect new information, events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.
Selected Financial Data | |||||||
(in thousands, except per share data) | |||||||
(unaudited) | |||||||
Three Months Ended | Six Months Ended | ||||||
June 30 | June 30 | ||||||
2022 | 2021 | 2022 | 2021 | ||||
Statement of Comprehensive Loss Data | |||||||
Revenue: | |||||||
Product sales | $ 570 | $ 392 | $ 1,012 | $ 843 | |||
Contract and other collaboration | - | 51 | - | 111 | |||
Total revenue | 570 | 443 | 1,012 | 954 | |||
Operating costs and expenses: | |||||||
Cost of goods sold (1) | 876 | 1,040 | 1,660 | 2,080 | |||
Research and development (1) | 1,544 | 724 | 2,859 | 1,693 | |||
Selling, general and administrative (1) | 6,822 | 8,694 | 14,160 | 16,338 | |||
Impairment of property and equipment | 4,901 | - | 4,901 | - | |||
Total operating costs and expenses | 14,143 | 10,458 | 23,580 | 20,111 | |||
Loss from operations | (13,573) | (10,015) | (22,568) | (19,157) | |||
Other income (expense): | |||||||
Interest expense | (327) | (614) | (717) | (1,286) | |||
Interest income and other income (expense), net | 51 | (16) | 89 | 60 | |||
Non-cash interest income on liability related to sale of future royalties | 463 | 799 | 1,136 | 1,581 | |||
Gain on termination of liability related to sale of future royalties | 84,052 | - | 84,052 | - | |||
Total other income (expense) | 84,239 | 169 | 84,560 | 355 | |||
Provision for income taxes | (3) | (5) | (3) | (5) | |||
Net income (loss) | $ 70,663 | $ (9,851) | $ 61,989 | $ (18,807) | |||
Basic net income (loss) per common share | $ 0.48 | $ (0.08) | $ 0.42 | $ (0.16) | |||
Shares used in computing basic net income (loss) per common share | 147,139 | 119,120 | 146,386 | 116,204 | |||
Diluted net income (loss) per common share | $ 0.48 | $ (0.08) | $ 0.42 | $ (0.16) | |||
Shares used in computing diluted net income (loss) per common share | 147,209 | 119,120 | 146,420 | 116,204 | |||
(1) Includes the following non-cash depreciation and stock-based compensation expense: | |||||||
Cost of goods sold | $ 64 | $ 70 | $ 131 | $ 148 | |||
Research and development | 239 | 200 | 500 | 381 | |||
Selling, general and administrative | 663 | 1,191 | 1,384 | 2,239 | |||
Total | $ 966 | $ 1,461 | $ 2,015 | $ 2,768 | |||
June 30, 2022 | December 31, 2021 | ||||||
Selected Balance Sheet Data | |||||||
Cash, cash equivalents, restricted cash and investments | $ 27,923 | $ 51,630 | |||||
Total assets | 56,133 | 77,893 | |||||
Total liabilities | 22,990 | 113,786 | |||||
Total stockholders' equity (deficit) | 33,143 | (35,893) | |||||
Reconciliation of Non-GAAP Financial Measures | |||||||
(Operating Expenses less impairment of property and equipment, depreciation and stock-based compensation expense) | |||||||
Three Months Ended | Six Months Ended | ||||||
June 30 | June 30 | ||||||
2022 | 2021 | 2022 | 2021 | ||||
Operating expenses (GAAP): | |||||||
Research and development | $ 1,544 | $ 724 | $ 2,859 | $ 1,693 | |||
Selling, general and administrative | 6,822 | 8,694 | 14,160 | 16,338 | |||
Impairment of property and equipment | 4,901 | - | 4,901 | - | |||
Total operating expenses | 13,267 | 9,418 | 21,920 | 18,031 | |||
Less impairment of property and | |||||||
equipment, depreciation and | |||||||
stock-based compensation expense | 5,803 | 1,391 | 6,785 | 2,620 | |||
Operating expenses (non-GAAP) | $ 7,464 | $ 8,027 | $ 15,135 | $ 15,411 | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corporate-update-301604552.html
SOURCE AcelRx Pharmaceuticals, Inc.
FAQ
What was AcelRx's revenue for Q2 2022?
How much did AcelRx gain from extinguishing debt?
What growth did DSUVIA experience in Q2 2022?
What is the status of Niyad™'s Emergency Use Authorization?
What is AcelRx's cash position as of June 30, 2022?
